Optogenetic Microsystem for Insulin Secretion Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type 1 diabetes, such as pancreatic islet cell transplantation, face challenges like significant islet destruction and a shortage of donor cells, leading to poor outcomes and the need for a new source of functional β-cells.
Innovation Solution
The use of optogenetics to control insulin secretion from stem cell-derived β-cells (SC-β-cells) grafted into the body, where a microchip system uses light to stimulate insulin release based on glucose levels, employing Channelrhodopsin-2 (ChR2) and ReaChR transduced cells, and an implanted microsystem with a glucose sensor and light emitting diodes to manage insulin and glucagon production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pancreatic islet cell transplantation is performed, then insulin secretion function is restored, but significant islet destruction occurs leading to poor outcomes
Solution Approach 1:
The patent segments the islet cell transplantation process by encapsulating individual islet cells or small clusters in protective microcapsules. Each microcapsule contains an islet cell surrounded by a semi-permeable membrane that allows nutrient and hormone exchange while protecting the cell from immune attack and physical damage. This segmentation approach maintains insulin secretion function while significantly reducing islet destruction.
Solution Approach 2:
The patent applies beforehand cushioning by pre-encapsulating islet cells in protective microcapsules before transplantation. The microcapsule shell provides preemptive protection against immune rejection, mechanical stress, and oxidative damage that would otherwise occur after transplantation. This prior protective measure significantly reduces post-transplantation islet destruction while maintaining functional integrity.
2Quantity of substance
If donor islet cells are used for transplantation, then functional β-cells can be provided, but a shortage of donor islets limits clinical application
Solution Approach 1:
The patent applies copying by creating artificial microcapsule copies that can be mass-produced through standardized manufacturing processes. Instead of relying on limited donor islets, the microcapsule technology enables production of numerous identical protective vessels that can accommodate islet cells. This copying approach decouples the quantity of functional β-cells available from the scarcity of donor islets, as the microcapsules themselves can be manufactured in large quantities.
Solution Approach 2:
The patent employs parameter changes by modifying the physical and chemical properties of the microcapsule shell to optimize protection and functionality. By adjusting parameters such as membrane porosity, thickness, composition, and surface properties, the system enhances cell survival and insulin secretion while maintaining manufacturability. These parameter optimizations enable scaling up production without proportionally increasing complexity.
3Ease of operation
If manual glucose monitoring is used to control insulin administration, then insulin levels can be adjusted, but continuous monitoring and manual intervention are required
Solution Approach 1:
The patent implements self-service by designing encapsulated islet cells with intrinsic glucose-sensing and insulin-secretion capabilities. The microcapsulated islet cells autonomously detect glucose level changes through their semi-permeable membranes and automatically secrete appropriate amounts of insulin in response, without requiring external monitoring or manual intervention. This self-regulating system restores natural insulin secretion physiology while eliminating the need for continuous manual glucose monitoring.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables automatic insulin release without manual glucose monitoring, enhancing insulin secretion efficiency and reducing the risk of islet destruction, thereby potentially improving treatment outcomes for Type 1 diabetes.
Implementation Method 1
said microsystem, comprising a light emitting diode stimulator comprising a plurality of light emitting diodes
Implementation Method 2
a glucose sensor, said glucose sensor generating a glucose level signal corresponding to a glucose level within the living body
Implementation Method 3
Optogenetics is a method that uses light to control select cells in living tissues
Implementation Method 4
an implanted microsystem is used to control Channelrhodopsin-2 (ChR2) and/or ReaChR (red-shifted ChR) transduced cells in vivo
Data Source
AI summary
A method and system for of treating type 1 includes implanting genetically modified islet cells under a capsule of or within an organ, implanting a microsystem adjacent the islet cells, said microsystem, comprising a light emitting diode stimulator comprising a plurality of light emitting diodes, determining a glucose level in a body and controlling the microsystem to selectively illuminate the islet cells to secrete insulin or glucagon or both based on the glucose level.